WELCOME TO R&D

We take our company's mission seriously: to extend and enhance human life.

Since 1858, we’ve been on the leading edge of science and technology to discover and develop new medicines. We measure our success by the innovative medicines we bring to patients, offering them new treatment options and, more importantly, new hope. Since 2002, our R&D team has helped to bring to market nine products in oncology, schizophrenia, depression, HIV/AIDS, hepatitis B and rheumatoid arthritis. Two of these medicines are biologics. In the fight against serious disease, biologics are playing an increasingly prominent role.

Yet, we are not satisfied with past success. So now, we are in the midst of a transformation to become a new kind of enterprise—a next-generation BioPharma company.

Our vision to become a next-generation BioPharma leader means we will combine the best elements of a traditional pharmaceutical company and those of a leading-edge biotech company by focusing on innovation, selective integration, and continuous improvement.

Our R&D strategy is to pursue significant areas of unmet medical need by leveraging our legacy in discovering and developing high-potency small molecules as well as our growing experience and expertise in highly targeted biologics.

Building on the past, accelerating to the future. It’s all part of what being a next-generation BioPharma leader is all about.